For the past 15 years Dr. Saag has devoted the majority of his career efforts to patient-oriented research in pharmacoepidemiology (drug safety and comparative effectiveness) research and evidence implementation (a branch of outcomes or Type 2 translational) research of the rheumatic diseases. In addition to competing successfully for peer reviewed funding, including the third renewal of his AHRQ supported Center for Education and Research on Therapeutics (CERTs) of musculoskeletal disorders, Dr. Saag has published or has in press 119 original scientific reports (75 with mentees as authors). Since the award of his K24 in 2005, Dr. Saag has served as a primary or secondary mentor for 22 pre and post- doctoral trainees. Along with his work as director of the CERTs, Dr. Saag's mentoring is facilitated by his role as director of the UAB Center for Outcomes, Effectiveness Research and Education and its T32 Health Services Research Training Grant. Renewal of his K24 grant would preserve Dr. Saag's protected time at 50% or greater effort and relieve future clinical and administrative responsibilities. Research proposed includes 3 current projects, 3 new projects and 4 future projects addressing novel questions about biologics agent safety in adults and children with inflammatory arthritis;evidence implementation research in osteoporosis;pharmacoepidemiology of osteoporosis examining adherence, comparative effectiveness, and bisphosphonate safety;and gout epidemiology. All the research proposed provide mentoring opportunities and make use of currently available large datasets, including national Medicare/Medicaid data. Dr. Saag will continue to recruit two or three new trainees into his research program each year, expand and refine his formal mentoring program using feedback received from trainees, and extend his leadership role in mentoring through the UAB Clinical &Translational Science Award (CTSA). UAB, its Schools, Departments, Divisions, and Interdisciplinary Research Centers provide an outstanding environment for the development of junior investigators in patient-oriented research. Based on institutional commitment and resources and Dr. Saag's successful record in research and mentoring, the renewal of Dr. Saag's K24 will maintain and greatly augment his ability to expand his research program aimed at developing the next generation of patient-oriented clinical investigators.

Public Health Relevance

During the past 15 years, Dr. Kenneth Saag has conducted funded patient-oriented research in the areas of drug safety, comparative effectiveness, and evidence implementation while engaged in mentoring the next generation of patient-oriented clinical investigators. Dr. Saag's research and mentoring opportunities are enhanced by his leadership with national research and mentoring organizations. Based on strong institutional commitment and resources as well as his success in training academic clinical researchers, a renewal of his K24 will maintain and expand his research and mentoring activities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AR052361-10
Application #
8731619
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Witter, James
Project Start
2005-06-01
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
10
Fiscal Year
2014
Total Cost
$196,414
Indirect Cost
$14,549
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Roblin, Douglas W; Zelman, David; Plummer, Sally et al. (2017) Evaluation of a ""Just-in-Time"" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial. Perm J 21:
Cram, Peter; Saag, Kenneth G; Lou, Yiyue et al. (2017) Racial Differences and Disparities in Osteoporosis-related Bone Health: Results From the PAADRN Randomized Controlled Trial. Med Care 55:561-568
Nguyen, V T; Edmonds, S W; Lou, Y et al. (2017) Validity, reliability, and responsiveness to change of the ""Osteoporosis and You"" knowledge scale. Osteoporos Int 28:3379-3388
Hall, Sylvie F; Edmonds, Stephanie W; Lou, Yiyue et al. (2017) Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003) 57:503-509
Wolinsky, F D; Lou, Y; Edmonds, S W et al. (2017) The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial. Osteoporos Int 28:3055-3060
Wolinsky, F D; Hall, S F; Lou, Y et al. (2017) The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial. Osteoporos Int 28:3061-3066
Saddekni, Michael B; Saag, Kenneth G; Dudenbostel, Tanja et al. (2016) The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials 50:238-44
Cram, P; Wolinsky, F D; Lou, Y et al. (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513-3524
Danila, Maria I; Outman, Ryan C; Rahn, Elizabeth J et al. (2016) A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. Contemp Clin Trials Commun 4:14-24
Edmonds, Stephanie W; Cram, Peter; Lou, Yiyue et al. (2016) Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: a randomized controlled trial. BMC Musculoskelet Disord 17:369

Showing the most recent 10 out of 56 publications